How effective is risk-reducing endocrine therapy for a BRCA gene mutation?

These medicines change the effect of hormones on breast cells. They are considered prevention rather than treatment for an existing cancer, and they do not remove the inherited BRCA change. Their protective effect is not the same for every breast cancer type, so a genetics or breast specialist may discuss whether the expected benefit fits your individual risk profile.

Possible drawbacks include hot flushes, changes in periods or sexual health, and effects on bones or blood vessels depending on the medicine. A clinician will review pregnancy plans, menopause status, medicines, and previous blood-clot or bone-health concerns before recommending an option.

Arrange a consultation that combines genetic counselling with breast-risk assessment. Ask how the BRCA1 or BRCA2 result changes the expected value of endocrine therapy, what screening remains necessary, and which alternatives should be compared. Do not start, stop, or share these medicines without medical advice.

Keep breast imaging and clinical follow-up on the schedule agreed with your team. Report troublesome effects early; adjusting the medicine or adding supportive care may make the plan more manageable.

Contact your care team promptly for a new breast or underarm lump, nipple discharge, skin or nipple change, or a persistent focal breast symptom. Seek urgent help for sudden chest pain, breathlessness, coughing blood, or one-sided leg swelling, particularly if you take a medicine associated with clotting risk.

Which endocrine medicine, if any, matches my mutation and menopausal status? How would you balance its possible benefit with effects on fertility, bones, blood clots, and daily life? What screening and risk-reducing options should accompany it?